United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 re

Decrease the percentage of people with Type 2 diabetes from 11.2% in 2014 to 10.1% by 2019.

The size of the North America Self-monitoring Blood Glucose Market was valued at USD 8.10 Million in 2023 and is projected to reach USD 12.99 Million by 2032, with an expected CAGR of 6.98% during the forecast period. Self-monitoring blood glucose is a relevant tool for patients with diabetes. Its process includes the regular testing of blood sugar to gauge how the body reacts to food, medicine, or physical activity. It helps increase peoples' awareness of their own choices and helps them avoid some complications that may come as a result of diabetes. The North American SMBG market is driven by the increasing incidences of diabetes, especially Type 2. The size and risk profile of the population are critical factors in North America. The region suffers from a rather large population that is susceptible to developing the disease primarily because of obesity, sedentary lifestyles, and aging. With the growth in awareness of diabetes, and with preventive and controlling features forming an important aspect of healthcare systems, the SMBG device and supplies market will continue to grow. The advances in technology, especially the available kinds of continuous glucose monitors, give market expansion way to more convenient and accurate blood sugar tracking. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

This statistic displays the crude prevalence rate of diagnosed diabetes among U.S. adults in 2016, by gender and diabetes type. According to the data, the crude prevalence rate of type II diabetes among male adults was 8.86 percent in 2016.

The Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high risk individuals with prediabetes.

The study enrolled overweight persons with elevated fasting and post-load plasma glucose concentrations. Participants were randomized to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The primary outcome measure was development of diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state, or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load. Participation in DPP continued after a diagnosis of diabetes was made, although study medication was discontinued and participants were sent to their local primary care provider for treatment of diabetes once fasting glucose was > 140 mg/dl.

Results showed that both lifestyle changes and treatment with metformin reduced the incidence of diabetes in persons at high risk compared with placebo. Furthermore, the lifestyle intervention was more effective than metformin in preventing the onset of diabetes.

Supplemental measurements were collected using biospecimens that were obtained during the original DPP clinical trial. These measurements included antibodies, biomarkers, hormones, and vitamin D levels to assess the relationships between sex hormones, diabetes risk factors, and the progression to diabetes. The supplemental data showed that sex hormones were associated with diabetes risk in men, but these associations were not found in women. Furthermore, obesity and glycemia were more important predictors of diabetes risk than sex hormones.

The size of the United States Self-Monitoring Blood Glucose Market was valued at USD 7.62 Million in 2023 and is projected to reach USD 11.76 Million by 2032, with an expected CAGR of 6.40% during the forecast period. SMBG, therefore, is an essential blood glucose tool for a person to take good care of his or her diabetes. In this technique, patients are empowered to choose their insulin dosage and diet, while making wise decisions in terms of exercise. This would prevent the complications of diabetes, such as heart disease, stroke, and renal failure. Rapidly increasing incidence of diabetes has accounted for significant growth in the market for SMBG in the United States. This market is also accelerated by heightened awareness of the requirement for tight blood sugar control and advancements in SMBG devices technology. SMBG devices-glucose meters, test strips, and lancets-are available over-the-counter through pharmacies and clinics as well as online merchants. The use of SMBG is very vital in the management of diabetes. Constant monitoring of blood glucose has benefited both type 1 and type 2 diabetic patients. Blood sugar fluctuation monitoring helps a person understand the fluctuations of blood sugar levels in their body and, by adapting lifestyle and medication, helps them gain control over their health, thus leading a better quality of life. Recent developments include: January, 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 20, 2022: Roche announced the launch of the COBAS pulse system in selected countries accepting the CE mark. The COBAS pulse system marks Roche Diagnostics' newest generation of connected point-of-care solutions for professional blood glucose management. The COBAS pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities like those of a smartphone. Following first commercial availability under the CE mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the Cobas Pulse System in other global markets.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Rising Diabetes Prevalence in the United States.

Digital Diabetes Prevention Programs Market Outlook

According to our latest research, the global Digital Diabetes Prevention Programs (DPP) market size reached USD 1.62 billion in 2024. The market is experiencing robust growth, with a recorded CAGR of 19.8% from 2025 to 2033. By the end of 2033, the market is projected to reach USD 7.93 billion. This surge is primarily driven by the increasing prevalence of prediabetes and type 2 diabetes worldwide, coupled with the growing adoption of digital health solutions that offer scalable, personalized, and data-driven approaches to diabetes prevention. As per our latest research, the digital diabetes prevention ecosystem is witnessing significant investment, technological advancements, and integration with broader digital health platforms, making it a pivotal segment in the global healthcare industry.

One of the primary growth factors fueling the expansion of the Digital Diabetes Prevention Programs market is the escalating global burden of diabetes and prediabetes. According to the International Diabetes Federation, over 540 million adults were living with diabetes in 2024, with millions more at risk due to prediabetes. This alarming trend has prompted healthcare systems, employers, and insurers to seek innovative, cost-effective solutions for risk reduction and early intervention. Digital DPPs leverage evidence-based curricula, behavioral science, and remote monitoring to deliver personalized interventions at scale. The convenience of accessing these programs through digital platforms—be it web-based portals, mobile applications, or telehealth—has significantly improved patient engagement and adherence, leading to better clinical outcomes and reduced healthcare costs.

Another critical driver of market growth is the rapid advancement and integration of technology within digital diabetes prevention solutions. Artificial intelligence, machine learning, and data analytics are being harnessed to deliver real-time feedback, adaptive coaching, and predictive risk assessments. These technologies enable continuous monitoring of user progress and allow for tailored interventions that address individual needs. Furthermore, the interoperability of digital DPPs with electronic health records (EHRs), wearable devices, and other digital health tools enhances the overall value proposition for healthcare providers and payers. The ability to seamlessly integrate digital DPPs into existing care pathways not only improves population health management but also supports value-based care initiatives by demonstrating measurable improvements in health outcomes.

The supportive regulatory landscape and increasing reimbursement opportunities are also contributing to the market’s upward trajectory. In several regions, including the United States and parts of Europe, digital DPPs have gained recognition from health authorities and insurance providers, paving the way for broader adoption. For instance, the US Centers for Medicare & Medicaid Services (CMS) has included digital DPPs in its reimbursement framework, encouraging both providers and patients to participate in these preventive programs. The COVID-19 pandemic has further accelerated the shift towards digital health, highlighting the importance of remote care and chronic disease prevention. As a result, stakeholders across the healthcare ecosystem—ranging from individuals to large employers and payers—are increasingly investing in digital DPPs as a strategic tool to curb the diabetes epidemic.

From a regional perspective, North America currently dominates the Digital Diabetes Prevention Programs market, accounting for the largest share in 2024, followed closely by Europe and the Asia Pacific. The high prevalence of diabetes, advanced digital infrastructure, and proactive healthcare policies in North America have created a fertile ground for digital DPP adoption. Europe is witnessing significant growth due to increasing government initiatives and rising awareness about preventive healthcare. Meanwhile, the Asia Pacific region is emerging as a high-growth market, driven by a surge in smartphone penetration, expanding internet access, and a growing middle class that is increasingly health-conscious. Latin America and the Middle East & Africa are also showing promising potential, albeit from a smaller base, as healthcare systems in these regions begin to embrace digital transformation and preventive care.

www.insight.hdrhub.org/about-us

Background: Diabetes mellitus affects over 3.9 million people in the United Kingdom (UK), with over 2.6 million people in England alone. More than 1 million people living with diabetes are acutely admitted to hospital due to complications of their illness every year. Cardiovascuar disease is the most prevalent cause of morbidity and mortality in people with diabetes. Diabetic retinopathy (DR) is a common microvascular complication of type 1 and type 2 diabetes and remains a major cause of vision loss and blindness in those of working age. This dataset includes the national screening diabetic grade category (seven categories from R0M0 to R3M1) from the Birmingham, Solihull and Black Country DR screening program (a member of the National Health Service (NHS) Diabetic Eye Screening Programme) and the University Hospitals Birmingham NHS Trust cardiac outcome data.

Geography: The West Midlands has a population of 5.9 million. The region includes a diverse ethnic, and socio-economic mix, with a higher than UK average of minority ethnic groups. It has a large number of elderly residents but is the youngest population in the UK. There are particularly high rates of diabetes, physical inactivity, obesity, and smoking.

Data sources:
1. The Birmingham, Solihull and Black Country Data Set, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. They manage over 200,000 diabetic patients, with longitudinal follow-up up to 15 years, making this the largest urban diabetic eye screening scheme in Europe. 2. The Electronic Health Records held at University Hospitals Birmingham NHS Foundation Trust is one of the largest NHS Trusts in England, providing direct acute services and specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds and 100 ITU beds. UHB runs a fully electronic healthcare record for systemic disease.

Scope: All Birmingham, Solihull and Black Country diabetic eye screened participants who have been admitted to UHB with a cardiac related health concern from 2006 onwards. Longitudinal and individually linked with their diabetic eye care from primary screening data and secondary care hospital cardiac outcome data including • Demographic information (including age, sex and ethnicity) • Diabetes status • Diabetes type • Length of time since diagnosis of diabetes • Visual acuity • The national screening diabetic screening grade category (seven categories from R0M0 to R3M1) • Diabetic eye clinical features • Reason for sight and severe sight impairment • ICD-10 and SNOMED-CT codes pertaining to cardiac disease • Outcome

Website: https://www.retinalscreening.co.uk/

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

Multicenter clinical research study aimed at discovering whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in study participants. At the beginning of the DPP, all 3,234 study participants were overweight and had blood glucose levels higher than normal but not high enough for a diagnosis of diabetesa condition called prediabetes. In addition, 45 percent of the participants were from minority groups-African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, or Pacific Islander-at increased risk of developing diabetes. The DPP found that participants who lost a modest amount of weight through dietary changes and increased physical activity sharply reduced their chances of developing diabetes. Taking metformin also reduced risk, although less dramatically. In the DPP, participants from 27 clinical centers around the United States were randomly divided into different treatment groups. The first group, called the lifestyle intervention group, received intensive training in diet, physical activity, and behavior modification. By eating less fat and fewer calories and exercising for a total of 150 minutes a week, they aimed to lose 7 percent of their body weight and maintain that loss. The second group took 850 mg of metformin twice a day. The third group received placebo pills instead of metformin. The metformin and placebo groups also received information about diet and exercise but no intensive motivational counseling. A fourth group was treated with the drug troglitazone (Rezulin), but this part of the study was discontinued after researchers discovered that troglitazone can cause serious liver damage. The participants in this group were followed but not included as one of the intervention groups. In the years since the DPP was completed, further analyses of DPP data continue to yield important insights into the value of lifestyle changes in helping people prevent type 2 diabetes and associated conditions. For example, one analysis confirmed that DPP participants carrying two copies of a gene variant, or mutation, that significantly increased their risk of developing diabetes benefited from lifestyle changes as much as or more than those without the gene variant. Another analysis found that weight loss was the main predictor of reduced risk for developing diabetes in DPP lifestyle intervention group participants. The authors concluded that diabetes risk reduction efforts should focus on weight loss, which is helped by increased exercise.

Snapshot img

Alpha Glucosidase Inhibitors Market Size 2024-2028

The alpha glucosidase inhibitors market size is forecast to increase by USD 476.8 million at a CAGR of 2.12% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of impaired glucose tolerance and obesity. The increasing awareness of diabetes and initiatives to improve quality healthcare services are key drivers for market expansion. Additionally, the aging population is a significant factor, as older adults are more susceptible to diabetes. Home healthcare services may also provide these medications for patients requiring long-term care. However, price pressure and the availability of counterfeit drugs pose challenges to market growth. To address these challenges, market players are focusing on developing effective strategies to ensure the availability of authentic and affordable drugs. The market is expected to continue its growth trajectory, providing opportunities for stakeholders to capitalize on this trend.

What will be the Size of the Alpha Glucosidase Inhibitors Market During the Forecast Period?

Request Free Sample

Alpha-glucosidase inhibitors are a class of medications used in the management of type 2 diabetes mellitus. These drugs help control postprandial hyperglycemia, or high blood sugar levels after meals, by inhibiting the digestive enzyme alpha-glucosidase. This, in turn, slows down the absorption of carbohydrates in the small intestine, thereby reducing the rise in blood glucose levels. Diabetes mellitus type 2, a chronic condition characterized by high blood sugar levels, affects millions of individuals in the US. The condition is often associated with complications such as renal damage, nerve damage, and ocular damage.
Impaired glucose tolerance and obesity are common risk factors for type 2 diabetes. Alpha-glucosidase inhibitors are used to manage diabetes-related complications by maintaining optimal blood sugar levels. These medications have been shown to help prevent or delay the onset of complications associated with diabetes. They are also effective in managing dumping syndrome, a condition characterized by rapid emptying of the stomach after meals, which can lead to hypoglycemia and other complications. However, the use of alpha-glucosidase inhibitors is not without risks. Hypoglycemia, or low blood sugar levels, can occur as a side effect of these medications. Lactic acidosis, a rare but serious condition, has also been reported in some cases.

How is this Alpha Glucosidase Inhibitors Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Disease Type

  Type 2 diabetes
  Dumping syndrome


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Disease Type Insights

The type 2 diabetes segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes, the most prevalent form of diabetes, arises when the body fails to effectively utilize insulin. This condition affects millions worldwide, with obesity and inactivity identified as primary risk factors. The onset of type 2 diabetes is often difficult to detect due to its subtle symptoms. Once diagnosed, however, proper management is crucial to prevent complications. Alpha glucosidase inhibitors, a type of advanced medication, play a significant role in managing type 2 diabetes. These inhibitors help regulate post-meal blood sugar levels by slowing down the digestion of carbohydrates in the small intestine. Three common alpha glucosidase inhibitors are Acarbose, Voglibose, and Miglitol.

In the context of the aging population and the increasing prevalence of impaired glucose tolerance, the demand for quality healthcare services offering these medications is on the rise. Alpha glucosidase inhibitors contribute to improving overall diabetes management, ensuring better health outcomes for patients.

Get a glance at the market report of share of various segments Request Free Sample

The Type 2 diabetes segment was valued at USD 2.68 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 45% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America experiences growth due to the rising incidence of type 2 diabetes and dumping syndrome in the region. Type 2 diabetes affects a significant popula

Snapshot img

Blood Glucose Monitoring Devices Market Size 2025-2029

The blood glucose monitoring devices market size is forecast to increase by USD 10.14 billion at a CAGR of 10% between 2024 and 2029.

The market is experiencing significant growth, driven by the rising global burden of diabetes and the increasing adoption of advanced technologies such as smart watch-based apps for continuous glucose monitoring. According to the International Diabetes Foundation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. This growing population of diabetes patients presents a substantial market opportunity for blood glucose monitoring device manufacturers. However, the market faces challenges that could hinder its growth potential. Regulatory hurdles impact adoption, as these devices must meet stringent regulatory requirements to ensure accuracy and safety.
Additionally, supply chain inconsistencies can pose challenges, as the demand for these devices is often volatile and requires a reliable and flexible supply chain to meet patient needs effectively. To capitalize on market opportunities and navigate these challenges, companies must focus on regulatory compliance, supply chain optimization, and the development of user-friendly and accurate devices that meet the evolving needs of diabetes patients. Technological advances in this field have led to more sophisticated devices, such as continuous glucose monitoring systems, insulin syringe and pens, which offer enhanced functionality and improved patient outcomes. The hospital end-use segment supports inpatient monitoring, while home healthcare segment devices empower individuals with convenient glucose monitoring solutions. By addressing these challenges, market participants can position themselves for long-term success in the market.

What will be the Size of the Blood Glucose Monitoring Devices Market during the forecast period?

Request Free Sample

The market is experiencing significant growth, driven by the increasing prevalence of diabetes and the demand for advanced technologies to support personalized diabetes management. Patient engagement is a key trend, with diabetes prevention programs emphasizing diet and exercise, and digital health solutions enabling remote patient monitoring through the Internet of Things. Artificial intelligence and machine learning are revolutionizing data analytics, enabling early detection of diabetes complications and improving quality of life through data interpretation. Diabetes research continues to advance, with innovation in sensor calibration and cloud computing enhancing the accuracy and accessibility of blood glucose monitoring.
The market encompasses a range of essential tools including glucose meters, lancets, and test strips, crucial for managing conditions like Type 2 diabetes. Innovations like Insulin pumps and Continuous Glucose Monitoring (CGM) systems such as Eversense CGM utilize advanced sensor technologies and microminiaturization. Diabetes awareness and education programs are also crucial, leveraging digital platforms to reach larger audiences and promote lifestyle modifications. Overall, the market is dynamic and innovative, with a focus on improving diabetes management and preventing complications.

How is this Blood Glucose Monitoring Devices Industry segmented?

The blood glucose monitoring devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals
  Home care
  Diagnostic centers


Product

  SMBG
  CGM
  Lancets


Indication

  Type-2 diabetes population
  Type-1 diabetes population


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

The diabetes care market encompasses various devices and technologies used for managing diabetes, with blood glucose monitoring devices being a crucial component. These devices include blood glucose meters, continuous glucose monitoring systems like Guardian Connect and Dexcom G6, and non-invasive glucose monitoring solutions. Diabetes educators and primary care physicians often recommend these tools for individuals with diabetes, including those with type 1, type 2, and gestational diabetes. Blood glucose meters provide instant readings, while continuous glucose monitoring systems offer real-time data logging and predictive capabilities. Wearable technology, such as insulin pumps and flash glucose monitoring systems like the Freestyle Libre, enable remote monitoring and data analysis

The global glucose tracking app market is experiencing robust growth, driven by the rising prevalence of diabetes and the increasing adoption of mobile health (mHealth) solutions. The market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This significant expansion is fueled by several key factors. Firstly, the increasing number of individuals diagnosed with diabetes, both type 1 and type 2, creates a substantial demand for convenient and effective blood glucose management tools. Secondly, the proliferation of smartphones and readily available internet access has made glucose tracking apps easily accessible to a wider population. Thirdly, these apps offer personalized features, such as medication reminders, dietary recommendations, and progress tracking, enhancing user engagement and efficacy in managing their condition. Furthermore, the integration of these apps with smart wearable devices like continuous glucose monitors (CGMs) further improves data accuracy and real-time monitoring capabilities. The cloud-based segment is expected to dominate the market due to its scalability, accessibility, and data sharing capabilities. Despite the positive outlook, certain challenges persist. Data privacy and security concerns, along with the need for regulatory approvals and interoperability between different apps and devices, pose significant hurdles. The market's growth will also be influenced by factors such as the cost of access to technology, digital literacy levels, and the adoption rate of telehealth services in various regions. The competitive landscape is characterized by established players and emerging startups, leading to continuous innovation and improvement in app functionalities and user experience. The market segmentation by application (personal vs. family) reflects the diverse needs of individuals and their families in managing diabetes. North America and Europe currently hold the largest market share, but growth potential is significant in developing economies in Asia and Africa as awareness and access improve.

According to Cognitive Market Research, the global Diabetes Management Apps market size will be USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 9.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
The Digital Diabetes Management Types of Services category is the fastest growing segment of the Diabetes Management Apps industry

Market Dynamics of Diabetes Management Apps Market

Key Drivers for Diabetes Management Apps Market

Growing Prevalence of Diabetes to Boost Market Growth

A key driver of the diabetes management apps market is the increasing global prevalence of both Type 1 and Type 2 diabetes. According to the International Diabetes Federation (IDF), millions of individuals are diagnosed with diabetes each year, creating a rising demand for effective management tools. Currently, 537 million adults (aged 20-79) are living with diabetes, which equates to 1 in 10 people worldwide. This figure is projected to grow to 643 million by 2030 and 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. In 2021, diabetes was responsible for 6.7 million deaths—equivalent to 1 death every 5 seconds—and accounted for at least USD 966 billion in health expenditures, a 316% increase over the past 15 years. Diabetes management apps provide a convenient solution for individuals to monitor blood glucose levels, track food intake, manage medications, and maintain physical activity.

Increasing Smartphone Penetration to Drive Market Growth

The widespread adoption of smartphones has provided an ideal platform for health apps, including diabetes management apps. According to the GSMA’s 2023 State of Mobile Internet Connectivity Report, 54% of the global population—around 4.3 billion people—now owns a smartphone. The global rollout of 4G and 5G networks has facilitated mobile broadband access, with over two-thirds (69%) of smartphone users on 4G-enabled devices and 17% on 5G-enabled devices, especially in advanced regions like North America and East Asia & Pacific. With increasing smartphone and mobile internet access, even in emerging markets, more people can download and use diabetes management apps for real-time health monitoring. This growing integration of healthcare into mobile devices, known as mHealth, is driving the development and adoption of diabetes management solutions.

Restraint Factor for the Diabetes Management Apps Market

Data Privacy and Security Concerns Will Limit Market Growth

One of the most significant barriers to the adoption of diabetes management apps is the growing concern over data privacy and security. These apps collect and store sensitive health information, including glucose levels, dietary habits, and medication schedules. Breaches in data security or inadequate data protection measures can result in personal health data being exposed or misused, leading to a lack of trust in these apps. Stringent data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., pose a challenge for app developers. Ensuring compliance with these regulations can be costly and time-consuming, potentially discouraging smaller developers from entering the market.

Impact of Covid-19 on the Diabetes Management Apps Market

COVID-19 led to a rapid expansion of telemedicine, with healthcare systems worldwide shifting to remote care to minimize in-person visits. For in...

According to the Juvenile Diabetes Research Foundation (JDRF), almost 1.25 million people in the United States (US) have type 1 diabetes, which makes them dependent on insulin injections. Nationwide, type 2 diabetes rates have nearly doubled in the past 20 years resulting in more than 29 million American adults with diabetes and another 86 million in a pre-diabetic state. The International Diabetes Federation (IDF)has estimated that there will be almost 650 million adult diabetic patients worldwide at the end of the next 20 years (excluding patients over the age of 80). At this time, pancreas transplantation is the only available cure for selected patients, but it is offered only to a small percentage of them due to organ shortage and the risks linked to immunosuppressive regimes. Currently, exogenous insulin therapy is still considered to be the gold standard when managing diabetes, though stem cell biology is recognized as one of the most promising strategies for restoring endocrine pancreatic function. However, many issues remain to be solved, and there are currently no recognized treatments for diabetes based on stem cells. In addition to stem cell research, severalβ-cell substitutive therapies have been explored in the recent era, including the use of acellular extracellular matrix scaffolding as a template for cellular seeding, thus providing an empty template to be repopulated with β-cells. Although this bioengineering approach still has to overcome important hurdles in regard to clinical application (including the origin of insulin producing cells as well as immune-related limitations), it could theoretically provide an inexhaustible source of bio-engineered pancreases Date Submitted: 2021-01-13

Snapshot img

Anti-Obesity Drugs Market Size 2025-2029

The anti-obesity drugs market size is forecast to increase by USD 22.91 billion at a CAGR of 15.7% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising obesity population, particularly in North America, is a major driver for this market. Additionally, research and development efforts are focused on creating drugs that can effectively manage both obesity and type 2 diabetes mellitus. This dual-action approach is gaining popularity as many obese individuals are also at risk for developing type 2 diabetes. Furthermore, the availability of telemedicine services and anti-obesity devices is making weight management more accessible and convenient for individuals. These trends are expected to continue fueling the growth of the market In the coming years. The use of anti-obesity drugs can help regulate insulin production and manage weight by reducing appetite and increasing metabolism. These drugs can have a positive impact on overall health and well-being, making them an essential tool In the fight against obesity and related health conditions.

What will be the Size of the Anti-Obesity Drugs Market During the Forecast Period?

Request Free Sample

The market encompasses a range of medicines designed to assist individuals struggling with weight management, targeting conditions such as obesity and overweight. These conditions are often linked to chronic diseases, including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, and various lifestyle-related illnesses. The prevalence of obesity and overweight continues to rise globally, driven by energy imbalance, with calories consumed exceeding calories expended. Factors contributing to this imbalance include appetite stimulation, metabolic disorders, and fat absorption. The market for anti-obesity drugs is expected to grow significantly due to the increasing burden of obesity and its associated health complications.
This trend is driven by the growing awareness of the health risks associated with obesity and the desire for effective weight loss solutions. The market caters to both adults and children and adolescents, addressing the rising prevalence of obesity across all age groups. The market's growth is further fueled by the increasing incidence of lifestyle-related factors, such as stress, smoking, and drinking, which contribute to weight gain.

How is this Anti-Obesity Drugs Industry segmented and which is the largest segment?

The anti-obesity drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Class III
  Class II anti-obesity drugs
  Class I anti-obesity drugs


Drug Class

  Peripherally acting drugs
  Centrally acting drugs


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Drug stores
  E-commerce


Route Of Administration

  Oral route
  Subcutaneous route


Geography

  North America

    Canada
    Mexico
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The class III segment is estimated to witness significant growth during the forecast period. The Class III segment dominates The market due to its focus on addressing severe obesity cases. This segment accounts for a significant market share and is expected to continue its leadership during the forecast period. The rise in research and development initiatives by pharmaceutical companies for novel anti-obesity drugs contributes to market expansion. However, it's important to note that pharmacotherapy for obesity can only achieve a certain reduction in Body Mass Index (BMI). Consequently, the Class III anti-obesity drugs segment may witness a decline during the forecast period as patients may require additional measures for sustained weight loss.
Obesity is a chronic condition with a global prevalence that fuels the demand for weight-loss medicines. These medicines target various mechanisms such as appetite suppression, metabolism enhancement, and fat absorption inhibition. Prevalent conditions associated with obesity include cardiovascular diseases, cancers, type-2 diabetes, and sleep apnea. The market caters to various distribution channels, including retail pharmacies, online pharmacies, and hospital pharmacies. Anti-obesity drugs can be administered through oral and subcutaneous routes.

Get a glance at the market report of share of various segments Request Free Sample

The class III segment was valued at USD 6.85 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 71% to the growth o

The European Continuous Glucose Monitoring (CGM) market is experiencing robust growth, projected to reach €2.04 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 11.33% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of diabetes, particularly type 1 and type 2, across Europe fuels demand for advanced glucose monitoring solutions. CGM systems offer superior accuracy and real-time data compared to traditional methods, empowering individuals to manage their condition more effectively and reduce the risk of severe hypoglycemic or hyperglycemic events. Technological advancements, including smaller, more comfortable sensor designs and improved data integration with mobile applications and insulin pumps, are further boosting market adoption. Government initiatives promoting diabetes management and reimbursement policies covering CGM devices also contribute to market growth. The market is segmented into sensors and durables, with sensors representing a significant portion due to recurring purchase needs. Key players like Abbott, Dexcom, Medtronic, and Senseonics are driving innovation and market competition, leading to improved product offerings and price competitiveness. The market is expected to witness particularly strong growth in countries such as Germany, the United Kingdom, and France, given their larger diabetic populations and well-established healthcare infrastructure. The competitive landscape is characterized by intense rivalry amongst established players and emerging companies. Market share analysis suggests a concentrated market with Abbott, Dexcom, and Medtronic holding a substantial portion. However, the presence of other players and ongoing innovations indicate a dynamic market with opportunities for both established players and new entrants. Restraints to market growth include high device costs, potential sensor inaccuracies in certain situations, and concerns about data privacy and security. Despite these challenges, the overall growth trajectory remains positive, underpinned by the unmet medical need and continuous technological improvements in CGM technology. Future growth will be significantly influenced by the development of advanced analytics, integration with artificial intelligence for personalized diabetes management, and expansion of access to CGM across various healthcare settings. Recent developments include: October 2023: Medtronic has recently introduced Simplera, a cutting-edge CGM designed for individuals with diabetes aged 2 and above. Currently undergoing FDA evaluation for clearance in the United States, Simplera boasts a modern, disposable design and eliminates the need for fingersticks., June 2022: Ascensia Diabetes Care, maker of the Contour blood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that its partner Senseonics Holdings, Inc., received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries.. Notable trends are: Continuous Glucose Monitoring Devices Prove to be an Instrumental Tool in maintaining Glycemic Balance.